Evaluation of a Community Health Program for the Prevention of Type 2 Diabetes and Other Cardio-metabolic Risk Factors in Adults: Districts of Barranquilla and Bogota, Colombia - January 2017 - December 2019

NCT ID: NCT03049839

Last Updated: 2019-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

650 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2019-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study is to evaluate the feasibility and effectiveness of a program for modifying lifestyles for diabetes prevention type 2 and control cardio-metabolic risk factors in adults with different categories of risk from the primary health care strategy.

The project will show the effect of these interventions for the first time in people With different risk of developing type 2 diabetes throughout the life in populations living in Colombia Located in 2 different cities, one of them in the interior of the country (districts of Bogota) and another in the north coast (districts of Barranquilla) .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular disease (CVD) and type 2 diabetes (T2D) are currently the public health problems fastest growing globally. According to the International Diabetes Federation (IDF) is estimated to have diabetes approximately 382 million people in the world. It is shown that early interventions in lifestyle can reduce the burden of type 2 diabetes and factors of cardiovascular modifiable risk.

This is an intervention study in cluster. 36-month integrated into 4 phases:

1. Design and adaptation of educational intervention
2. Population Screening
3. Stepwise intervention program
4. Evaluation results.

For population screening test FINDRISC validated for the Latin American population will be employed and a score of 12 will be considered as a cutoff to all who have a score equal to or greater than 12 (moderate or high risk) they perform a test oral glucose tolerance (OGTT) according to the results 3 groups will be established

* High risk group: Subjects with FINDRISC score ≥12 and impaired glucose tolerance (IGT)
* Moderate risk group: Subjects with FINDRISC score ≥12 and impaired fasting glucose or norm tolerant
* Low risk group: Subjects with FINDRISC score \<12.

Intervention program: One year of duration, 3 types of programs are established.

* Lifestyle Intervention program\_ Communitarian: Intervention program at Community level with Low risk group.
* Lifestyle Intervention program\_ Informative: Program information intervention for the group with moderate risk.
* Lifestyle Intervention program\_ structured: intervention program for members of high-risk group.

An evaluation of the different variables are studied at baseline and the final of the intervention in the three groups established.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prediabetic State

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention_ structured

One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)

Group Type EXPERIMENTAL

Intervention_ S

Intervention Type BEHAVIORAL

One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))

Intervention_ Informative

Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).

There is a single group session where they receive information to prevent cardiomatabolic risk factors

Group Type EXPERIMENTAL

Intervention_ I

Intervention Type BEHAVIORAL

One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)

Intervention_ Communitarian

One year, Intervention program at Community level. People with a FINDRISC less than 12 points.

Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors

Group Type EXPERIMENTAL

Intervention_ C

Intervention Type BEHAVIORAL

One year, Intervention program at Community level. People with a FINDRISC less than 12 points

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention_ S

One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))

Intervention Type BEHAVIORAL

Intervention_ I

One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)

Intervention Type BEHAVIORAL

Intervention_ C

One year, Intervention program at Community level. People with a FINDRISC less than 12 points

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LIP_Structures LIP_Informative LIP_Communitarian

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People over age 30 years, residents within the perimeter of the conglomerate in the districts of Barranquilla and Bogota
* Wishing to participate and sign informed consent

Exclusion Criteria

* DT2 known and / or treated
* History of diseases or events that prevent their participation
* Neurological disability that does not allow you to make own decisions
* Pregnant women
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad del Norte

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tania Acosta, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Universidad del Norte

Pablo Achner, MD, ENDOCRINOLOGIST

Role: PRINCIPAL_INVESTIGATOR

ASOCIACIÓN COLOMBIANA DE DIABETES

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidad Del Norte

Barranquilla, , Colombia

Site Status RECRUITING

Asociación Colombiana de Diabetes

Bogotá, , Colombia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Colombia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tania Acosta

Role: CONTACT

00573106331321

Pablo Aschner

Role: CONTACT

00573106331321

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

tania Acosta, MD, MPH, PhD

Role: primary

00573106331321

Pablo Aschner, MD

Role: primary

00573102118652

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

55657

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Latinos Combating Diabetes
NCT01831921 COMPLETED NA
Feel4Diabetes-study
NCT02393872 UNKNOWN NA